Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous G-CSF for Stem Cell Mobilization in Autologous HSCT
IRCT20100127003210N29Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in hematopoietic malignancies (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Stem cell mobilization efficacy. Started Jan 2025; status: completed.
02
Drugs
filgrastim
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on IRCT20100127003210N29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100127003210N29.